Dyslipidemia and cardiovascular risk: The importance of early prevention

QJM: An International Journal of Medicine

Volumn 102, Issue 9, 2009, Pages 657-667

  Miller, M ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; ORAL ANTIDIABETIC AGENT; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE DURATION; DYSLIPIDEMIA; DYSPEPSIA; ERUCTATION; FLU LIKE SYNDROME; FLUSHING; GLYCEMIC CONTROL; HOT FLUSH; HUMAN; INFECTION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METABOLIC SYNDROME X; MONOTHERAPY; MUSCLE DISEASE; MYALGIA; MYOPATHY; MYOSITIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RHABDOMYOLYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 69249212383     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcp065     Document Type: Article

References (85)

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with MI in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-52.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002; 106:3143-421.
3. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
4. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al.; American Diabetes Association; American College of Cardiology Foundation. Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31:811-22.
5. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
6. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-35.
7. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-504.
8. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79:8-15.
9. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115:450-8.
10. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309-16.
11. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. Br Med J 2009; 338:b92.
12. Cohen JD, Cziraky MJ, Jacobson TA, Wallace A, Cai C. Changes in the prevalence of abnormal lipid fractions among US adults: Results from the National Health and Nutrition Examination Survey II, III and 1999-2006. Circulation 2008; 118:S_1081-2 [Abstract 1198].
13. Centers for Disease Control and Prevention (CDC), National Diabetes Surveillance System. Diabetes data and trends. CDC Web site. [http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm] Accessed June 2007.
14. Miller M. Disorders of hypertriglyceridemia. In: Kwiterovich PO, ed. The Johns Hopkins Textbook of Dyslipidemia. Baltimore, MD, Lippincott, Williams & Wilkins, 2009.
15. Lamarche B, Tchernof A, Mauriège P, Cantin B, Dagenais GR, Lupien PJ, et al. Fasting insulin and apoplipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279:1955-61.
16. Sattar N, Williams K, Sniderman AD, D'Agostino R Jr, Haffner SM. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with metabolic syndrome. Circulation 2004; 110 2687-93.
17. Sierra-Johnson J, Somers VK, Kuniyoshi FH, Garza CA, Isley WL, Gami AS, et al. Comparison of apoliprotein B-apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol 2006; 98:1369-73.
18. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. PROVE-IT TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 trial. J Am Coll Cardiol 2008; 51:724-30.
19. Jacobson TA, Case CC, Roberts S, Buckley A, Murtaugh KM, Sung JC, et al. Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obes Metab 2004; 6:353-62.
20. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al.; American Heart Association Nutrition Committee. Diet and lifestyle recommendations revision 2006: A scientific statement from the American Heart Association Nutrition Committee. Circulation 2006; 114:82-96.
21. Chiuve SE, McCullough ML, Sacks FM, Rimm EB. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: Benefits among users and nonusers of lipid-lowering and antihypertensive medications. Circulation 2006; 114:160-7.
22. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 2008; 371 117-25.
23. Girman CJ, Rhodes T, Mercuri M, Pyörälä K, Kjekshus J, Pedersen TR, et al.; 4S Group; AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93:136-41.
24. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357:1301-10.
25. Chapman MJ. Fibrates in 2003: Therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003; 171:1-13.
26. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: From receptors to drug discovery. J Med Chem 2000; 22:717-26.
27. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, et al.; DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: The Diabetes Atherosclerosis Study (DAIS). Circulation 2003; 107:1733-7.
28. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, et al. Pleiotrophic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22:717-26.
29. Devchand P, Keller H, Peters J, Vazquez M, Gonzalez F, Wahli W. The PPARα-leucotriene B4 pathway to inflammation control. Nature 1996; 384:39-43.
30. Simpson IA, Lorimer AR, Walker ID, Davidson JF. Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia. Thromb Haemostat 1989; 54:442-4.
31. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart study: Primary prevention trial with gemfibrozil in middle - aged men with dyslipidemia. N Engl J Med 1987; 317 1237-45.
32. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, et al. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation 1992; 85: 37-45.
33. The Bezafibrate Infarction Prevention (BIP) study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102:21-7.
34. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165:1154-60.
35. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-8.
36. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002; 162:2597-604.
37. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al.; FIELD study investigators. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005; 366:1849-61.
38. Scott R, O'Brien R, Fulcher G, Pardy C, d'Emden M, Tse D, et al.; on behalf of the FIELD Study Investigators. The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: The FIELD study. Diabetes Care 2008; 32:493-8.
39. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al.; FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 2007; 370:1687-97.
40. Burgess D, Hunt D, Li LP, Zhang J, Sy R, Laakso M, et al.; on behalf of the FIELD Investigators. Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: The Fenofibrate Intervention and Event Lowering in Diabetes FIELD) study. Circulation 2007; 116 II_838 [abstract].
41. Morgan JM, Capuzzi DM, Guyton JR, Centor RM, Goldberg R, Robbins DC, et al. Treatment effect of NIASPAN, a controlled-release nicotinic acid, in patients with hypercholesterolemia: A placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996; 1:195-202.
42. Goldberg A, Alagona P Jr, Capuzzi DM, Guyton J, Morgan JM, Rodgers J, et al. Multiple-dose efficacy and safety of an extended-release form of nicotinic acid in the management of hyperlipidemia. Am J Cardiol 2000; 85:1100-5.
43. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360-81.
44. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8 1245-55.
45. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005; 95:254-7.
46. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, et al.; Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med 2002; 162:1568-76.
47. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31(Suppl. 1):S12-54.
48. Lai E, De Lepeleire I, Crumley TM, Liu F, Wenning LA, Michiels N, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype1. Clin Pharmacol Ther 2007; 81:49-57.
49. Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008; 101: 625-30.
50. Stalenhoef AF, de Graaf J, Wittekoek ME, Bredie SJ, Demacker PN, Kastelein JJ. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis. 2000; 153:129-38.
51. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, et al; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007; 29:1354-67.
52. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343 1454-9.
53. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet 1999; 354:447-55.
54. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al.; Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1223-30.
55. Leaf A. Omega-3 fatty acids and prevention of arrhythmias. Curr Opin Lipidol 2007; 18:31-4.
56. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al.; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007; 369:1090-8.
57. Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/ day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003; 91: 956-60.
58. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005; 95:462-8.
59. Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study. Am Heart J 2009; 157:195-203.
60. Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. Atherosclerosis 2008; 32:493-8.
61. McKenney JM, Farnier M, Lo KW, Bays HE, Perevozkaya I, Carlson G, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006; 47:1584-7.
62. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, et al; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007; 29:1354-67.
63. Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 2008; 102:429-33.
64. McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, et al Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007; 192:432-7.
65. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol 2008; 101:1428-36.
66. Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: The OCEANS study. Am J Cardiovasc Drugs 2008; 8:69-81.
67. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005; 95:462-8.
68. Farnier M, Freeman MW, Macdonell G, Perevozskaya I, Davies MJ, Mitchel YB, et al.; The Ezetimibe Study Group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005; 26:897-905.
69. Farnier M, Roth E, Gil-Extremera B, Mendez GF, Macdonell G, Hamlin C, et al.; Ezetimibe/Simvastatin + Fenofibrate Study Group. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 2007; 153 1-8.
70. Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 2008; 51:1564-72.
71. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007; 99(Suppl.):3C-18C.
72. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116:408-16.
73. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95 120-2.
74. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30:1280-7.
75. Pan WJ, Gustavson LE, Achari R, Rieser MJ, Ye X, Gutterman C, et al Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000; 40:316-23.
76. Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003; 25:459-71.
77. Bergman AJ, Murphy G, Burke J, Zhao JJ, Valesky R, Liu L, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004; 44:1054-62.
78. Zhu T, Awni WM, Hosmane B, Kelly MT, Sleep DJ, Stolzenbach JC, et al ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol 2009; 49:63-71.
79. FDA approves fenofibric acid for lipid target controls [http://www.endocrinetoday.com/view.aspx?rid=35718] Accessed January 20, 2009
80. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345 1583-92.
81. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110 3512-7.
82. Clinical Trial: AIM HIGH: Niacin plus statin to prevent vascular events. Heart Protection Study-Treatment of HDL to Reduce the Incidence of Vascular Events. [www.clinicaltrials.gov.ct/show/NCT00120289] Accessed 24 April 2008.
83. Cinical Trial. HPS2-Thrive Study. Heart Protection Study-Treatment of HDL to Reduce the Incidence of Vascular Events. [http://www.ctsu.ox.ac.uk/pressreleases/2006-05-31/ hps2-thrive-press-release] Accessed 7 April 2008.
84. Clinical Trial. ACCORD: Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. [http://www.clinicaltrials.gov/ct/show/ NCT00000620] Accessed 20 April 2008.
85. Clinical Trial. IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin. NCT00202878. [http://clinicaltrials.gov/show/NCT00202878] Accessed 19 December 2008.